Review Reports
- Marilize Van der Walt 1,*,
- Sarah E. Jones 1 and
- Samantha J. M. Evans 7
- et al.
Reviewer 1: Claudia Cerracchio Reviewer 2: Anonymous Reviewer 3: Anonymous Reviewer 4: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsIn this manuscript the authors present a study about the treatment of 17 cats, affected (or likely to be) by FIP and FIV and/or FeLV at the same time, with GS-441524. The purpose of the study is certainly of general scientific interest, considering the considerable difficulties in the treatment of FIP, which may be worst in the presence of a retroviral co-infection, such as those caused by FIV or FeLV. In general, the manuscript is well written and structured. No objections were found regarding the use of the English language. Some doubts, however, were found due to the limits of the investigation method used, as, as also described by the authors themselves, the test and the data collected through it cannot be defined as exhaustive for a complete picture of all the cats analyzed. Nevertheless, the biggest doubt concerns the presentation of the results. In fact, in its current state, it is believed that this paragraph could be improved for greater comprehensibility. Additionally, where possible, it is suggested to use more recent bibliography.
Comments for author File:
Comments.pdf
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsThis is a survey-based study on GS-441524 treatment in FeLV/FIV-positive cats with presumptive effusive FIP, an under-reported population. The work is clinically relevant and generally well presented. I recommend revision focused on clarifying methods, data presentation, and the strength of inferences.
The study explicitly acknowledges that FIP was presumptively diagnosed and sometimes not veterinarian-confirmed or supported by FIP-specific tests. I suggest making this even clearer in the Methods and Results by indicating, for each cat or at least as totals, how many had full veterinary work-up with FIP-specific tests, partial work-up, reported diagnosis only. Any comparisons with previously published GS-441524 cohorts with more stringent case confirmation should be clearly framed as tentative.
With such a small cohort, inferential statistics have very low power. Please emphasise in the Results/Discussion that comparisons between FeLV vs FIV (age, interval to FIP, survival) are exploratory. Where you report “no significant difference,” consider adding a short phrase (“…likely reflecting limited power”) and avoid over-interpreting trends.
The dosing description (starting ~7 mg/kg/day, dose increases, treatment extensions, retreatment of relapses) is clinically valuable. It would help to state more explicitly whether doses/durations were owner-reported vs veterinarian-documented, and to present a concise summary (e.g. median dose and duration, proportion escalated/extended) in one paragraph or a simple table.
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Reviewer 3 Report
Comments and Suggestions for AuthorsMajor concerns:
- The sample size of this study is too small, and the statistical data is based on questionnaire surveys, which may lead to biased statistical results. Please note in the discussion that the data has not been independently verified and is provided by non-professionals reporting veterinary diagnostic information.
- Please provide the diagnostic criteria for FIP.
- Please provide the source for GS-441524 and the reason for the differences in the dosing regimen.
Minor concerns:
- A comprehensive revision of English grammar, syntax, and spelling throughout the manuscript is strongly recommended to enhance readability and academic rigor. (Line 48: fatal4.; Line 96: group19.)
- Legends are somewhat lengthy and need to be streamlined.
- The p-value retains the same number of decimal places.
Comments for author File:
Comments.pdf
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Reviewer 4 Report
Comments and Suggestions for AuthorsThe manuscript addresses a clinically important question: whether retrovirus-positive cats with effusive FIP have comparable outcomes when treated with GS-441524. The topic is relevant to practitioners and shelters, and the authors provide long-term follow-up for a subset of cats, which is valuable. However, the study’s main weakness is that it is survey-based with variable diagnostic confirmation, including cases diagnosed online and several cats lacking FIP-specific testing. As written, the manuscript sometimes reads as though it is reporting outcomes for confirmed FIP, when in fact it is largely presumptive FIP, and the diagnostic heterogeneity is substantial. This is not fatal, but the paper must be revised to tighten the case definition, be more transparent about diagnostic uncertainty and missingness, and avoid overinterpretation of the survival and relapse estimates given the small sample size and estimated dates. Overall, I think the manuscript is potentially publishable, but it requires major revision focused on methodological clarity, bias/limitations, and more cautious interpretation.
- You state that cats were “presumptively diagnosed with FIP” (which is fine), but the diagnostic variability is extreme: Three cats were “diagnosed…online” based on vet results, and none of these had FIP-specific testing (p. 6–7)… Six cats had neither effusion testing (beyond gross exam) nor FCoV/FIP-specific testing (p. 6)…. Only a small subset had RT-PCR/mRNA PCR, Rivalta, cytology, or complete effusion analysis (Table 4, p. 7). You are reporting 94% 12-week survival and 82% one-year survival and comparing to literature outcomes for FIP therapy. Those claims need a more defensible “FIP likelihood” framework, or the conclusions must be toned down. Add a structured case definition (even if retrospective) using categories such as: high confidence effusive FIP: effusion analysis consistent with FIP (high protein, Rivalta+, cytology supportive) ± FCoV/FIP PCR or 7b ELISA. Moderate confidence: effusion present + typical clinicopathologic pattern (hyperglobulinemia/low A:G) + response to antiviral. Low confidence: effusion only + minimal supportive testing. Then report outcomes stratified by confidence category, or at minimum include a sensitivity analysis excluding the lowest confidence cases. In the Abstract and Conclusion, explicitly state: “presumptive effusive FIP based on survey responses” and avoid implying confirmed diagnosis.
- The recruitment method is through social media treatment groups and shelters (p. 3), which strongly predisposes toward: owners who found treatment and persisted, communities where success stories are more likely to remain engaged, and underrepresentation of cats that died early or never started therapy. You mention this briefly (Discussion limitations), but the manuscript still reads as a generalizable estimate of success. Strengthen the limitations section with explicit statements that survival estimates likely overestimate effectiveness relative to a full clinical population. Avoid causal language such as “supports antiviral treatment…in these populations” unless you specify the observational nature and bias. Consider reframing the objective to: “describe caregiver-reported clinical features and outcomes in a convenience sample”.
- Retrovirus testing is heterogeneous: POC antibody, p27 antigen, PCR, IFA (Table 4, p. 7–8). But the paper does not clearly distinguish: FeLV progressive vs regressive vs abortive, whether positive results were confirmed or transient, and whether cats were viremic vs proviral-positive only. This directly impacts the comparison you draw about outcomes and neoplasia. Add a clear table footnote or text specifying which tests were used for each retrovirus and what counts as “positive” in this study. If you can’t classify FeLV infection outcome, state it explicitly in Methods as a core limitation rather than only in Discussion. If any cats had discordant results (e.g., POC positive but PCR negative), that should be described.
- You use Mann–Whitney tests and Kaplan–Meier curves (p. 3), but: sample sizes are tiny (FeLV-only n≈9, FIV-only n≈6, coinfected n=2), several key dates are estimated and truncated (p. 3), three cats are lost to follow-up (p. 3). Report exact n for each analysis (FeLV-only vs FIV-only excluding coinfected). For Kaplan Meier: specify censorship rules and clarify which dates were estimated. Consider presenting survival descriptively (median with range) and treat inferential stats as exploratory. In Results, avoid borderline interpretations (e.g., p=0.052) as meaningful without emphasizing low power.
- You state the survey was in 2022–2023 and dosing was about half of current recommendations (Discussion, p. 12). This is important context, but the paper must be careful not to imply these outcomes represent current standard-of-care dosing. Make a clearer statement in Abstract/Discussion: “These outcomes reflect an early-era, non-standardized treatment environment with variable product quality and dosing.” If possible, report outcomes by whether cats were later treated with regulated compounded products vs unlicensed, if that info exists. If not, state it as unknown.
- Table 1 (p. 4): add explicit missing-data notation for cats lost to follow-up (right now “- Unanswered and lost to follow up” is easy to miss). Also clarify whether “Survival in months” is calculated to last contact or death date; you define it, but the table includes “Alive at follow up” mixed with numeric survival and “Lost to follow up.”
- Table 5 (p. 8-9): there is a formatting issue (“Treatment details… .” double punctuation). Also clarify “Weeks to additional relapse” and blank fields; use NA consistently.
- Figure 2 (p. 10): the figure is simple but doesn’t show variability or denominators clearly. Add the exact number of cats contributing to each timepoint.
- Figure 3 (p. 11–12): in a small dataset with estimated dates, KM curves can be misleading. If kept, include a note: “Dates include estimates/truncations for some cats.”
- You write that resolution with antiviral supports presumptive diagnosis (Discussion, p. 14). That is plausible, but it can also reflect treatment of other inflammatory/infectious processes (especially given concurrent antibiotics/steroids in some cases). You should treat response as supportive but not confirmatory.
- Three cats developed neurologic signs after starting therapy (p. 6), and you suggest low dosing + immunosuppression could allow CNS persistence (p. 12). This is an interesting hypothesis but is speculative. Please: mark as hypothesis, acknowledge alternative explanations (unrelated neurologic disease, toxin exposure, seizures unrelated to FIP), and clarify whether relapse was confirmed clinically/diagnostically vs assumed.
- Inclusion: “treatment plans for at least 12 weeks” (p. 3), yet one cat only completed 8 weeks due to leukemia (p. 8). This is okay, but clarify that they remained included because intent-to-treat or because therapy was initiated.
- Provide a brief flow: respondents (26) => excluded (9 non-effusive) => included (17) => follow-up available (14). This is already partly described but would benefit from a clean structured paragraph.
What I would need to recommend acceptance in the next round: a clearer, more defensible case definition for presumptive effusive FIP, with outcomes stratified or sensitivity analysis excluding low-confidence cases. Stronger and more explicit handling of bias/limitations (convenience sample, survey-based data, estimated dates). More cautious wording of conclusions, avoid implying generalizable efficacy estimates. Clean-up of tables/figures and consistent reporting of missingness, denominators, and definitions.
Comments on the Quality of English LanguageOverall the English is readable, but there are repeated small issues that should be cleaned up. I recommend a careful proofread focused on punctuation, spacing, and consistency. Examples from the current version: Missing space and typo: “uniformly fatal4.” in Introduction (p. 2) should be “uniformly fatal [4].” Inconsistent hyphenation: “follow up” vs “follow-up” appears both ways (e.g., p. 3-4). Choose one (prefer “follow-up” as adjective, “follow up” as verb). Apostrophe usage: “cat ID’s” (p. 3) should be “cat IDs”. Awkward phrasing: “This causes significantly shorter survival in cats with FeLV than cats without” (p. 2). Consider: “Cats with FeLV have significantly shorter survival than FeLV-negative cats.” Precision: “medical grade drugs became widely available at much lower cost” (p. 2). Consider: “regulated compounded formulations became available…” (medical-grade can be interpreted as FDA-approved, which is not necessarily true). Consistency of units: mg/kg/day appears as “mg/kg/d” in tables and “mg/kg/day” in text. Standardize. Minor formatting: Double periods, inconsistent em-dash usage, and some line-break hyphenation artifacts (“Colo-rado”) typical of PDF export; ensure the final submission is clean. These are straightforward copyedits; the more important language issue is avoiding overconfident phrasing given the observational design.
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsFollowing the revisions made by the authors, the manuscript is suitable for publication in its current form. Indeed, no objections or issues are found, as the article is easy to read and understand.
Author Response
Comment: Following the revisions made by the authors, the manuscript is suitable for publication in its current form. Indeed, no objections or issues are found, as the article is easy to read and understand.
Response: Thank you for taking the time to review our manuscript. We appreciate your valuable feedback from the previous round and are happy to hear your response in round 2. Please see the submission for this round for final changes.
Reviewer 4 Report
Comments and Suggestions for AuthorsI thank the authors for the careful revision of the manuscript and for their detailed point-by-point responses. The revised version is improved in several ways. In particular, the manuscript now more clearly acknowledges the survey-based nature of the data, the presumptive nature of the FIP diagnoses, the diagnostic heterogeneity across cases, and the limitations of generalizability associated with a convenience sample. The addition of a “low confidence” diagnostic category, the sensitivity-style survival summary excluding those low-confidence cats, the more cautious framing of relapse and neurologic interpretations, and the stronger discussion of sample bias are all helpful improvements. Overall, the manuscript is stronger and more transparent than the previous version. That said, a few issues still remain. These are no longer major conceptual flaws, but they still affect interpretive precision and publication readiness. In my view, the paper is now close to acceptable, but it would still benefit from minor revision before final acceptance:
- The authors added a low-confidence category and identified the six cats who fall into it. They also explicitly revised the Abstract and Discussion to refer to “presumptive effusive FIP based on survey responses”, which is an important correction. The addition of survival calculations excluding low-confidence cats is also helpful and directly responsive to the earlier concern. However, I still think the manuscript would benefit from slightly clearer wording in the Results and Discussion to avoid the impression that the low-/higher-confidence distinction represents a fully validated retrospective classification. It is a useful descriptive framework, but still a rough one based on incomplete self-reported data. I suggest softening that framing just slightly, for example by clarifying that this categorization was applied retrospectively to help contextualize diagnostic uncertainty. This is a minor wording issue, not a major concern.
- The revised manuscript now states more clearly that the study may overestimate effectiveness relative to a broader clinical population and that the convenience sample may not be representative. This change is important and improves the paper substantially. I still recommend one final tightening of the concluding paragraph. The sentence: “these findings could support antiviral treatment of FIP in these populations” is better than the previous wording, but it still feels slightly stronger than necessary given the observational design and self-reported nature of the data. A more cautious phrasing such as: “these findings are consistent with the possibility that antiviral treatment can be successful in these populations” would better match the overall evidence level. Again, this is a minor issue of tone and inference.
- The authors now explicitly acknowledge that FeLV stage of infection could not be determined and frame this as a core limitation of interpretation. That is an important and necessary correction. However, the manuscript still occasionally moves quite quickly from descriptive findings into biologically interpretive statements about FeLV vs FIV pathogenesis. These are interesting hypotheses, but the text should remain careful not to imply that the present dataset can distinguish pathobiological mechanisms rather than only clinical patterns. The relevant Discussion section is improved, but some sentences could still be slightly softened.
- The final paragraph still includes language such as: “this report provides evidence that the response to treatments for cats with presumptive FIP and concurrent retroviral infection is similar to that of FIP alone”. I think this should be softened. The study is small, non-randomized, survey-based, and diagnostically heterogeneous. The data are encouraging, but “provides evidence” of similarity is slightly too assertive. I recommend revising such phrasing toward: “this report suggests that treatment responses in some retrovirus-positive cats with presumptive FIP may be comparable to previously reported outcomes…” This would keep the conclusion accurate while still preserving the paper’s value. Similarly, the sentence: “In the authors’ opinion, retroviral infection should not preclude treatment for FIP in cats.” reads more like a clinical position statement than a data-driven conclusion. It may be reasonable as expert opinion, but in this manuscript it should be presented more cautiously or removed. A better phrasing might be: “These findings suggest that retroviral coinfection alone should not automatically preclude consideration of antiviral treatment, although prognosis may still be influenced by concurrent retrovirus-associated disease.” That would be much better aligned with the evidence presented.
The authors have addressed most of the major concerns raised in the first round, and the manuscript is substantially improved. The remaining issues are relatively minor and mainly concern: further softening of a few interpretive conclusions, more precise wording of ethics/consent language, and a final language/style cleanup. With those revisions, I believe the manuscript would be suitable for publication.
Author Response
Please see attached document.
Author Response File:
Author Response.pdf